Quantcast

Latest National Institute for Health and Clinical Excellence Stories

2008-08-07 12:00:18

PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published today. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Charities expressed outrage at the decision, saying it left patients only one treatment option - interferon - to which many do not respond. Professor John Wagstaff, from the...

2008-08-07 12:00:18

By JANE KIRBY Broadcaster James Whale accused a health watchdog today of being "barbaric" in denying kidney cancer patients access to four drugs. The star, who was diagnosed with the disease in 2000 and set up a charity to raise awareness, said the National Institute for Health and Clinical Excellence (Nice) was a "very badly named organisation". He slammed Nice's decision - which is subject to appeal - to deny patients access to Sutent (sunitinib), Avastin (bevacizumab), Nexavar...

2008-08-07 09:01:05

GlaxoSmithKline plans to renegotiate with the UK's Department of Health as part of its attempt to reverse the National Health Service's decision regarding the company's cancer drug Tyverb, reported the Financial Times. According to the news source, GlaxoSmithKline (GSK) is proposing a new 'price-volume' deal to address the concerns of the National Institute for Health and Clinical Excellence (NICE), the government's medicines advisory body, which considers Tyverb as too costly when compared...

2008-08-07 09:10:00

By Barry Nelson PATIENTS with advanced kidney cancer were dealt a devastating blow last night when spending watchdogs effectively banned four life- giving drugs on the NHS. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent, Avastin, Nexavar and Torisel as too expensive. Charities expressed outrage at the decision, saying it left patients only one treatment option ? interferon ? which is not as effective for many sufferers....

2008-07-28 18:00:41

Lord Darzi's recent plan for the NHS may only have concerned England, but his ideas for speeding up the drug appraisals process could have implications for the All Wales Medicines Strategy Group. Health Wales spoke to Professor Philip Routlege, chair of the group about what happens next THE speed at which new breakthrough drugs and treatments are appraised for use on the NHS has long been a thorny issue. Despite devolution and the considerable divergence of health policy between Wales and...

2008-07-08 12:00:16

The medical advisory panel to the UK National Health Service has recommended that GlaxoSmithKline's Tyverb should not be used on the NHS to treat advanced metastatic breast cancer on the grounds that it is not effective enough to justify its cost. This decision represents not only a blow to GSK but also casts doubt on how many other new cancer therapies will be available in the UK. The UK panel ruled that, based on data showing that the median survival time for women who received Tyverb...

2008-07-08 09:00:12

The National Institute of Health and Clinical Excellence has advised against the use of GlaxoSmithKline's oral cancer drug Tyverb in the UK's National Health Service, reported the Financial Times. According to the Financial Times, The National Institute of Health and Clinical Excellence (NICE) has issued a provisional recommendation that Tyverb for advanced breast cancer failed to meet its threshold for clinical and cost effectiveness. GSK tried to negotiate a 'risk-sharing' arrangement...

2008-07-05 00:00:23

THOSE people faced with the threat of losing their sight will rejoice that a treatment is now available on the NHS in Yorkshire which might prevent this terrible prospect. However, this hugely welcome news should not be allowed to erase the memory of the unnecessarily tortuous battle that campaigners have had to fight to reach this major landmark. The National Institute for Health and Clinical Excellence took months to reach a decision over Lucentis, deliberations that culminated in...

2008-07-05 00:00:06

In a nutshell Government drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has approved a controversial weight-loss drug for use on the NHS. Acomplia, manufactured by Sanofi-Aventis, is licensed in the UK as an adjunct to diet and exercise for the treatment of obese and overweight patients with type 2 diabetes or dyslipidaemia. It was launched in the UK in June 2006. What's the problem? Rimonabant, the drug's compound name, is banned in the US over fears...

2008-07-01 06:00:49

By Lyndsay Moss Health Correspondent DENYING patients free treatment because they choose to pay for drugs not available on the NHS is inhumane, the leader of Scotland's doctors says. Dr Peter Terry, chairman of the British Medical Association (BMA) in Scotland, said many terminally ill patients were looking for lifelines and should not be denied the chance to buy drugs not provided by the NHS. So-called "co-payments" are not allowed within the NHS in Scotland, meaning those who want...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related